MSN, Sandoz Settle Sunovion's IP Suit Over Latuda Generics
By Bonnie Eslinger ( July 5, 2018, 4:36 PM EDT) -- A New Jersey federal judge Thursday dismissed Sunovion Pharmaceuticals Inc.'s patent infringement suit against MSN Laboratories and Sandoz Inc. over its bipolar medication Latuda after the parties reached a deal and MSN agreed to delay its generic version of the drug until Sunovion's patent expires....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.